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The transforming growth factor beta (TGF-b)/activin superfamily
is comprised of multifunctional and ubiquitous peptides with roles
in many areas of cell biology. Three different isoforms of TGF-b,
designated as TGF-b1, -b2 and -b3, with similar but not identical
biological activities, have been identified in various mammalian
tissues and cells (Barnard et al, 1990; Sporn et al, 1992). The intra-
cellular biological effects of TGF-b are initiated following ligand
binding to oligomeric complexes of high affinity TGF-b type I and
type II receptors (TGF-b RI and TGF-b RII). If one of the recep-
tors is absent or inactivated, the cells lose their responsiveness to
TGF-b. cDNAs encoding mammalian type II receptor for TGF-b
and activin have been cloned, and each of these receptors is a
transmembrane serine/threonine kinase (Mathew et al, 1991; Lin
et al, 1992). Using polymerase chain reaction (PCR) cloning
approaches, a series of novel serine/threonine kinase receptors
(SKRs) and activin-receptor-like kinases (ALKs) have been iden-
tified (He et al, 1993; ten Dijke et al, 1993; Matsuzaki et al, 1993;
Xu et al, 1994). ALK-5 has been shown to be a signalling type I
receptor for TGF-b (Franzen et al, 1993), whereas SKR1 and
SKR2 have been shown to be activin type I receptors (ten Dijke et
al, 1994; Xu et al, 1995; Matsuzaki et al, 1996). The type I
receptor kinase domains are more similar to each other than they
are to the type II receptor kinase domains. Signalling by these
receptors is mediated by the recently identified Smad protein
family. Upon phosphorylation by activated receptors, Smads 
form complexes, move into the nucleus, associate with DNA-
binding proteins and activate gene transcription (Massagué et al,
1997)
One of the most prominent effects of TGF-b in vitro is a
pronounced inhibition of epithelial cell growth (Robert et al,
1985). However, it is well known that cancers typically demon-
strate resistance to the growth inhibitory effect of TGF-b (Serra et
al, 1996). In the colorectal adenoma–carcinoma sequence (Muto et
al, 1975), the conversion of the non-tumorigenic phenotype of
human colonic adenoma cell lines to the tumorigenic phenotype is
accompanied by a reduced response to the growth inhibitory
effects of TGF-b (Manning et al, 1991). Furthermore, most colon
cancer cells are resistant to the anti-proliferative effects of TGF-b
(Hoosein et al, 1989). Loss of the growth inhibitory response to
TGF-b at the cellular level is probably a more important step in the
malignant progression. In addition, possible mechanisms by which
TGF-b facilitates the progression of tumour growth include
immunosuppression, angiogenesis and changes in the extracellular
matrix (Sporn et al, 1988).
Modulation of growth factor effects can be achieved by various
mechanisms, including changes in ligand concentration, activation
of latent forms of the ligand, modulation of number and affinity of
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receptors, and alterations in post-receptor pathways. Several
reports indicate that elevated levels of TGF-b mRNA and protein
in colorectal cancer are associated with cancer progression
(Tsushima et al, 1996). If TGF-b is indeed an inhibitor for epithe-
lial cells, how then do colorectal cancer cells manage to proliferate
despite elevated TGF-b production by tumour cells? Concerning
the mechanisms of resistance to the anti-proliferative effects of
TGF-b in colorectal cancer, Markowitz et al (1995) identified a
specific TGF-b RII mutation that is associated with defective
DNA mismatch repair in colon cancer cells. However, numerous
reports also indicate that transcriptional regulation makes an
important contribution to determination of the expression level of
TGF-b receptors (Birchenall-Roberts et al, 1995; Kim et al, 1997).
Accordingly, to clarify the mechanisms of resistance to the anti-
proliferative effects of TGF-b in vivo, we estimated the transcrip-
tional level of TGF-b receptors in colorectal cancer using in situ
hybridization and Northern blot hybridization as the standard for
those in normal colorectal epithelial cells.
In addition, no studies of human colorectal tumour to date have
compared in situ levels of TGF-b1 with those of its receptors as a
presumptive target gene, and with the presence of ligand protein.
To ascertain if TGF-b from colorectal cancer acts as paracrine
factor on mesenchymal cells, we analysed the distributions of
TGF-b and its receptors by a combination of in situ hybridization
of TGF-b1 receptors and its ligand, and the immunohistochemistry
of TGF-b1.
MATERIALS AND METHODS
Tumour specimens
Twenty-two advanced colorectal cancer specimens and 11
adenoma specimens were obtained from patients at Kansai
Medical University Hospital. Ten men and 12 women with an age
range of 38–81 years (mean age, 60 years at diagnosis) were
included in advanced cancer cases, and seven men and four
women with an age range of 45–72 years (mean age, 53 years at
diagnosis) in adenoma cases. The tumours were diagnosed histo-
logically as colorectal adenoma or cancers. Adjacent non-involved
colorectal mucosa was also examined in all cases. These patients
had undergone partial colorectomy or polypectomy between
January 1996 and March 1998. Informed consent was obtained
from every patient. In all cases, tissue samples were quickly
embedded in OCT compound (Miles, Elkhart, IN, USA), frozen in
dry ice–acetone and stored at –80°C until analysis.
A section from each specimen block was stained with haema-
toxylin–eosin for histological evaluation, and representative
blocks were chosen for in situ hybridization and immunohisto-
chemistry. In addition, non-involved colorectal mucosa adjacent to
the tumour was used as an internal positive control for TGF-b and
their receptors. Tumours were examined by an experienced
observer without knowledge of staining results.
Eleven cases of colorectal adenoma tissues were shown in a
proportion of cases with mild (n = 4), moderate (n = 5) and severe
Table 1 Clinical profiles of patients studied and mRNA expressions of TGF-b1, TGF-b RI and TGF-b RII and TGF-b1 immunoreactivity in human colorectal
cancers
Staining
mRNA expression levelb intensityb
Tumour size
TGF-b RI TGF-b RII TGF-b1 TGF-b1
Case Site (cm ´ cm) pTNMa pTNM stagea Histology Nor. Ca. Nor. Ca. Nor. Ca. Nor. Ca.
1 Transverse 3.2 ´ 4.4 T4,N1,M0 III Moderate 2+ – 2+ ± +++ +
2 Sigmoid 3.8 ´ 2.9 T2,N0,M0 I Well 2+ – 2+ ± +++ +
3 Ascending 4.8 ´ 7.4 T3,N0,M0 II Well 2+ – 2+ ± +2 +++
4 Sigmoid 3.8 ´ 4.2 T3,N0,M0 II Moderate 2+ ± 2+ ± +++ 2 +
5 Rectum 4.9 ´ 4.5 T3,N1,M0 III Moderate 2+ ± 2+ ± +++ 2 +
6 Sigmoid 4.0 ´ 4.4 T3,N1,M1 IV Moderate 2+ ± 2+ ± +++ 2 +
7 Rectum 4.8 ´ 7.8 T4,N0,M0 III Moderate 2+ ± 2+ ± +++ 2 +
8 Sigmoid 4.3 ´ 5.6 T3,N2,M0 III Moderate 2+ ± 2+ ± +++ +
9 Sigmoid 4.8 ´ 3.4 T4,N1,M1 IV Moderate 2+ 2+ 2+ + + + + +
10 Ascending 2.5 ´ 3.2 T3,N0,M0 II Moderate 2+ 2+ 2+ + + ± +2 +
11 Sigmoid 4.5 ´ 6.4 T3,N2,M0 III Moderate 2+ 2+ 2+ 2+ + + + 2+
12 Rectum 4.8 ´ 6.0 T4,N2,M1 IV Well 2+ 2+ 2+ 2+ + + + 2+
13 Rectum 3.6 ´ 4.8 T4,N3,M1 IV Moderate 2+ 2+ 2+ 2+ + + + +
14 Sigmoid 4.0 ´ 5.2 T3,N0,M0 II Moderate 2+ 2+ 2+ 2+ + + + +
15 Sigmoid 4.4 ´ 5.4 T3,N0,M0 II Well 2+ 2+ 2+ 2+ + + + 2+
16 Ascending 9.0 ´ 10.1 T3,N0,M0 II Moderate 2+ 2+ 2+ 2+ + + + 2+
17 Descending 4.2 ´ 5.3 T3,N1,M0 III Moderate 2+ 2+ 2+ 2+ + + + 2+
18 Ascending 7.3 ´ 4.2 T3,N1,M0 III Poor 2+ 2+ 2+ 2+ + + + 2+
19 Rectum 4.4 ´ 3.7 T3,N0,M0 II Moderate 2+ 2+ 2+ 2+ + + + 2+
20 Transverse 5.0 ´ 7.5 T3,N3,M0 III Well 2+ 2+ 2+ 2+ + + + 2+
21 Sigmoid 4.3 ´ 5.4 T3,N1,M0 III Moderate 2+ 2+ 2+ 2+ + + + 2+
22 Descending 4.8 ´ 7.2 T3,N0,M0 II Moderate 2+ 2+ 2+ 2+ + + + 2+
Nor., normal colorectal epithelial cells; Ca., cancer cells. apTNM classification. pT: extent of the primary tumour; pN: regional lymph node metastasis; pM; distant
metastasis. bThe first three parameters were graded as follows; –, no; ±, faint; +, moderate; 2 +, intense.196 M Matsushita et al
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atypia (n = 2). No adenoma tissues contained cancer cells.
Colorectal cancers were histologically classified as well (n = 5),
moderately (n = 16) and poorly differentiated adenocarcinoma 
(n = 1). Tumours were localized at the ascending colon (n = 4),
transverse colon (n = 2), descending colon (n = 2), sigmoid colon
(n = 9) and rectum (n = 5). Duke’s classification was graded as A
(n = 9), B (n = 1), C (n = 8) and D (n = 4) (Table 1). The tumours
were staged at the time of surgery by the standard criteria for 
TNM staging using the unified international colorectal cancer
staging classification (Hutter et al, 1986).
In situ hybridization
RNA probe
Hybridization was performed using the following cDNA probes:
0.30-kb fragment of rat TGF-b1 (Qian et al, 1990); 0.37-kb PCR
fragment (forward primer, 5¢-CGGAAGCTTACAGTGTTTCTGC-
CACCTCT-3¢; reverse primer, 5¢-GATAAGCTTCGATGGTGAAT-
GACAGTGCG-3¢) of human TGF-b RI (Franzen et al, 1993);
0.61-kb PCR fragment (forward primer, 5¢-TAAGGATCCTATGAC-
GAGCAGCGGGGTCTG-3¢; reverse primer, 5¢-GGCGAATTCG-
A B
C D
E F
Figure 1 Differential expression patterns of TGF-b RI, TGF-b RII and TGF-b1 mRNA in human colon cancer and non-involved normal colon mucosa by in situ
hybridization. (A) In situ hybridization with antisense probe to TGF-b RI shows a high level of message (mRNA expression) prominently in human normal colon
epithelial cells (right side), but no mRNA expression in cancer cells (left side). (C) In situ hybridization with antisense probe to TGF-b RII shows high levels of
mRNA prominently in normal colon epithelial cells (right side), but low levels of mRNA in cancer cells (left side). (E) In situ hybridization with antisense probe to
TGF-b1 shows high levels of mRNA both in human normal colon epithelial cells (right side) and in cancer cells (left side). In situ hybridization with a sense probe
to TGF-b RI (B), TGF-b RII (D) and TGF-b1 (F) shows no signal above background on a sequential section of the same sample. Bars: 100 mmTGF-b receptors in colorectal cancer 197
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GTTTCCCAGGTTGAACT-3¢) of human TGF-b RII (Lin et al,
1992). To avoid cross-hybridization between TGF-b RI and TGF-b
RII, we chose extracellular domains of TGF-b RI and TGF-b RII
cDNA. We also used the latent associated peptide portion of rat TGF-
b1 cDNA, which does not have any homology to TGF-b2 or -b3. All
the cDNAs were subcloned into pBluescript II KS (+) vector
(Stratagene Inc., La Jolla, CA, USA). Sense and antisense RNA
probes were transcribed in vitro in the presence of digoxigenin-11-
UTP (Boehringer Mannheim, GmbH, Mannheim, Germany). The
transcription reactions were carried out for 2 h at 37°C in 20 ml of 1 ´
transcription buffer (50 mM Tris-HCl, 10 mM magnesium chloride
(MgCl2), 5 mM dithioerythritol, 0.1 mM EDTA at pH 7.2) containing
1 mg of the template DNA, 1 mM each of GTP, CTP and ATP, 
0.65 mM UTP, 0.35 mM digoxigenin-11-UTP, 20 units of ribo-
nuclease inhibitor and 20 units of T3 or T7 RNA polymerase
(Boehringer Mannheim). After transcription, the DNA templates
were digested with DNase I (Boehringer Mannheim) for 15 min at
37°C. Riboprobes were precipitated with ethanol and LiCl, and then
resuspended in diethylpyrocarbonate-treated water.
Hybridization
Frozen tissue sections (6 mm thick) were digested with 10 mg ml–1
of proteinase K (Boehringer Mannheim) for 10 min and rinsed in
phosphate-buffered saline (PBS), pH 7.4, then placed in 0.2 N HCl
for 5 min at room temperature. Before hybridization, tissue
sections were acetylated in a 0.25% solution of acetic anhydride in
100 mM triethanolamine, pH 8.0, for 10 min at room temperature,
rinsed in PBS and dehydrated in 70, 80, 90 and 100% ethanol.
Colon sections then were hybridized in 50% formamide, 10 mM
Tris-HCl pH 7.6, 250 ng ml–1 yeast RNA, 250 ng ml–1 salmon
sperm DNA, 1 ´ Denhardt’s solution, 10% dextran sulfate, 
600 mM NaCl and 1–2 mg ml–1 digoxigenin-labelled riboprobe for
16 h at 50°C in a formamide-saturated humidified chamber.
Subsequently, hybridization products were rinsed in 5 ´ saline–
sodium citrate (SSC) and then in 50% formamide, 5 ´ SSC for 
30 min. After washing in 2 ´ SSC, 0.2 ´ SSC, 0.2 ´ SSC each for
20 min, they were rinsed in 100 mM Tris-HCl, pH 7.5 and 150 mM
NaCl. To reduce non-specific background, sections were incu-
bated twice in 100 mM Tris-HCl, pH 7.5, 150 mM NaCl containing
0.2% Tween 20. The sections were incubated with alkaline
phosphate-labelled anti-digoxigenin antibody at 1:300 dilution
(Boehringer Mannheim) for 1 h at room temperature, and subse-
quently incubated with the enzyme reaction mixture (100 mM Tris-
HCl, pH 9.5, 100 mM NaCl, 50 mM MgCl2) containing nitroblue
tetrazolium and 5-bromo-4-chloro-indolylphosphate (Boehringer
Mannheim) several times at room temperature. The resultant
sections were dehydrated, coverslipped and examined under a
light microscope with bright-field illumination.
Immunohistochemistry
Frozen tissue sections (4 mm thick) were air-dried, fixed with acetone
at 4°C for 10 min and treated with PBS containing 0.03% hydrogen
peroxide (H2O2) for 30 min at room temperature. After pre-incuba-
tion with PBS containing normal goat serum for 30 min at room
temperature to block non-specific binding, sections were incubated
with 1 mg ml–1 affinity-purified rabbit polyclonal anti-TGF-b1 anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in a humid-
ified chamber at 4°C overnight. For a negative control, the
anti-TGF-b1 antibody was absorbed with excess immunized peptide
(10 mgm l –1) (Santa Cruz Biotechnology) for 2 h at room tempera-
ture. Next, tissue sections were washed thoroughly with PBS, incu-
bated with biotinylated goat anti-rabbit IgG (Vector Laboratories,
Burlingame, CA, USA) at room temperature for 40 min and then
with biotin–avidin–peroxidase reagent (Vector Laboratories) at room
temperature for 30 min. The bound immunocomplex was visualized
by incubation with 0.02% 3,3¢-deaminobenzidine tetrahydrochloride
A
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Figure 2 Localization of TGF-b RI and TGF-b RII mRNAs in human colon
adenoma by in situ hybridization. (A) Haematoxylin–eosin staining shows
tubular adenoma with moderate atypia. (B) In situ hybridization with
antisense probe to TGF-b RI shows high levels of mRNA prominently in
human adenoma cells. (C) In situ hybridization with antisense probe to TGF-
b RII shows a similar level of mRNA in the adenoma cells. Bars: 100 mm198 M Matsushita et al
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Figure 3 Northern blot hybridization analyses of TGF-b1, TGF-b RI and TGF-b RII mRNAs in normal colorectal mucosa, colorectal adenoma and colorectal
cancer. (A) Northern blot hybridization was performed with poly-A RNAs (4 mg per lane) extracted from normal colorectal mucosa, colorectal adenoma and
colorectal cancer. Blots were hybridized with 32P-labelled random-primed cDNA probes for GAPDH, TGF-b1, TGF-b RI and TGF-b RII. The lower panel shows
GAPDH mRNA expression. (B) The levels of TGF-b1 and TGF-b receptor mRNAs in colorectal adenoma and colorectal cancer relative to normal colorectal
mucosa were quantified by densitometric scanning. Normal colorectal mucosa was assigned a value of 1 and other values expressed relative to these were
plotted. N, normal colorectal mucosa; A, colorectal adenoma; C, colorectal cancer
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Figure 4 Immunohistochemical staining with TGF-b1 antibody in human colon cancer. (A) Haematoxylin–eosin staining of a sequential section shown in Figure
1, indicating cancer cells (left side), adjacent noninvolved normal colon mucosa (right side) and their interstitium. (B) The distribution of brown cytoplasmic
staining of TGF-b1 protein is shown in the human colon cancer cells and adjacent non-involved normal colon mucosa on a sequential section. There is weak
immunostaining for TGF-b1 in normal human colon crypts and interstitial cells. In contrast, strong immunostaining for TGF-b1 is observed in the cytoplasm of
human colon cancer cells. (C) High power views of a cancerous area on a sequential section show the strong signal for TGF-b1 in the cytoplasm of human colon
cancer (open arrow). Smooth muscle cells and the stroma in the connective tissue show fibrillar staining for TGF-b1 (closed arrow). (D) The signal is specifically
inhibited by the addition of excess TGF-b1 peptide. Bars: (A, B, D) 100 mm; (C) 50 mmTGF-b receptors in colorectal cancer 199
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in PBS containing 0.006% H2O2 for several minutes. Finally, the
sections were counterstained lightly with Mayer haematoxylin
(Sigma Diagnostics, St Louis, MO, USA).
Interpretation of in situ hybridization and
immunohistochemistry
Staining was scored independently by two observers (MM and
KM), and a high level of concordance (90%) was achieved. In
cases of disagreement, the slides were reviewed and a consensus
view achieved. Staining was scored in a semiquantitative fashion
from – to 2+: –, denoting no staining; ±, faint staining; +, moderate
staining; 2+, strong staining (Table 1). For in situ hybridization of
TGF-b receptors, we standardized the normal membranous pattern
of staining as 2+. Because the staining pattern often varied within
the same tumour, particularly when the degree of differentiation
varied, the score was based on the dominant pattern.
Northern blot hybridization
TGF-b1, TGF-b RI and RII cDNAs used for in situ hybridization
and 1.1 kb fragment of human glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; Clonetech, Palo Alto, CA, USA) were
labelled with a-[32P]-dCTP (3000 Ci mmol–1; Amersham
International) by the random primer labelling method. Total RNA
was isolated from frozen tissues by extraction in guanidinium
isothiocyanate–phenol–chloroform, and polyadenosine-A-rich
RNA was selected using oligo (dT)-cellulose (New England
Biolabs Inc., Beverly, MA, USA). Aliquots of 4 mg of poly-rich
RNA were denatured with 2.2 M formaldehyde/50% formamide,
electrophoresed through 1% agarose gels containing 2.2 M
formaldehyde and transferred onto nylon membranes (Hybond-N+
RPN303B; Amersham International, Buckinghamshire, UK). The
GAPDH cDNA was labelled with 32P (3000 Ci mmol–1;
Amersham International) by the random primer labelling method.
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Figure 5 Localization of TGF-b RI and TGF-b RII transcripts and TGF-b1 protein in vimentin-positive fibroblast-like cells and endothelial cells in colorectal
cancer stroma. (A) Immunohistochemistry with TGF-b1 antibody shows that TGF-b1 protein is localized in the colorectal cancer cells (arrowhead), the tumour-
associated vascular endothelial cells (open arrow) and in the fibroblast-like cells (closed arrow) in the surrounding tissue stroma. Bars: 100 mm. (B) Immuno-
histochemistry with vimentin antibody shows that the protein is also detected in the fibroblast-like cells (closed arrow) and endothelial cells (open arrow) in
cancer stroma. Bar: 50 mm. (C) and D) Staining of the serial sections of cancer stroma with antisense riboprobe specific for TGF-b receptors. The grey stain
indicates the location of TGF-b receptor messages. (C) Antisense section to show TGF-b RI message in endothelial cells (open arrow) adjacent to the colorectal
cancer cells and the fibroblasts or myofibroblast cells (closed arrow) in colorectal cancer stroma, respectively. Cells expressing TGF-b RII mRNA were often
closely associated with TGF-b RI expressing fibroblast cells and endothelial cells in colorectal cancer stroma (D). Bars: 50 mmThe filters were hybridized with the probe in solution containing
40% formamide, 5 ´ Denhardt’s solution, 5 ´ saline–sodium phos-
phate–EDTA (SSPE), 0.5% sodium dodecyl sulphate (SDS) and
100 mgm l –1 sonicated salmon testis DNA for 16 h at 42°C. After
washing with 2 ´ SSC containing 0.1% SDS at 55°C, the filters
were exposed to RX film (Fuji Photo Film Co., Kanagawa, Japan).
After autoradiography, the filters were boiled in 0.5% SDS for 
10 min to strip off the radioactive probes and rehybridized with
32P-labelled DNA probes for TGF-b1, TGF-b RI and TGF-b RII in
a similar manner.
Immunofluorescence study
The affinity-purified rabbit polyclonal anti-Smad 4 antibody
(Nakao et al, 1997) was a generous gift from Dr ten Dijke (Ludwig
Institute for Cancer Research). After washing with PBS, the
tumour specimens were minced with scissors and digested with
Dulbecco’s modified Eagle’s medium (DMEM) containing 0.1%
collagenase and dispase (Boehringer Mannheim, Mannheim,
Germany) and incubated for 1 h at 37°C. Cells were then cultured
onto LAB TEK chambers (Nunc, Naperville, IL, USA) and
cultured for 1 week at 37°C in 5% carbon dioxide in air. Cells were
washed with PBS and incubated for 1 h in DMEM in the presence
or absence of 10 ng ml–1 TGF-b1 (R&D Systems, Minneapolis,
MN, USA) at 37°C for 1 h. Slides were washed once with PBS,
fixed with 4% para-formaldehyde/PBS containing 5% sucrose for
10 min, permeabilized with 0.2% Triton X100 in PBS for 30 s, and
washed four times. To block non-specific binding, slides were
incubated in PBS containing 10% normal goat serum for 30 min at
room temperature and then with primary antibody at 1:1000 at 4°C
for 16 h in a humidified chamber. After four washes, 1 mg ml–1
FluoroLinkTM Cy2TM labelled goat anti-rabbit IgG (H&L)
(Amersham Life Science, Arlington Heights, IL, USA) was added,
and the slides incubated for 30 min at room temperature with three
subsequent washes. The slides were mounted with Perma FluorTM
Aqueous Mounting Medium (Shandon Lipshaw, Pittsburgh, PA,
USA). The cells were observed by fluorescence microscope.
RESULTS
Colorectal cancer
TGF-b receptor mRNA expression
We summarized the histological classification, size, TNM classifi-
cation and the grades of TGF-b RI, RII and TGF-b1 transcripts and
TGF-b1 protein expressions in human colorectal cancer (Table 1).
Figure 1 shows differential expression patterns of TGF-b RI,
RII and TGF-b1 mRNA by in situ hybridization in human colon
cancer and non-involved normal colon mucosa from patient no. 2
in Table 1. The strongest signal for TGF-b RI mRNA was found
ubiquitously in all normal colorectal epithelial cells (Figure 1A).
Cells expressing TGF-b RII mRNA were usually associated with
TGF-b RI-expressing epithelial cells in normal colorectal mucosa
(Figure 1C).
In contrast to the high level expression of TGF-b RI transcript in
normal colorectal epithelial cells, colorectal cancer cells in 8/22
(38%) cases only faintly, if at all, expressed TGF-b RI mRNA
(Table 1, Figure 1A). Moreover, faint TGF-b RII mRNA signals
were observed in the cancer cells of 8/22 (38%) cases (Table 1,
Figure 1C). The down-regulation was usually greater for TGF-b RI
than for TGF-b RII, and 8/22 (38%) cases showed down-regulation
of both receptor transcripts in the cancer cells (Table 1). We
conclude that these signals are specific, because in situ hybridiza-
tion with a sense probe to each TGF-b receptor showed no signal
above background on a sequential section of the same sample
(Figure 1B, D). It is notable that the distribution of mRNA expres-
sion for fibroblast growth factor receptor 1 (FGFR1), which
promotes cell growth as an oncogene, was completely reversed
compared with TGF-b receptor. Unlike the expression pattern of
TGF-b receptor mRNAs, FGFR1 mRNA expression was not
detected in normal colorectal epithelial cells, but progressively
increased in cancer cells (data not shown). In other colorectal
cancer cases, both TGF-b RI and RII mRNA signals were detected
intensely in the cancer cells. The tumour size, pTNM classification
and histological classification of colon cancer did not correlate with
differences in the distribution of TGF-b receptor-expressing cells.
TGF-b1 mRNA expression
The signal for TGF-b1 mRNA was found ubiquitously in normal
crypt. Strong and moderate signals of TGF-b1 mRNA were
observed in the cancer cells of 1/22 (5%) and 20/22 (90%) cases
respectively (Table 1 and Figure 1E). In situ hybridization with a
sense probe to TGF-b1 showed no signal above background on a
sequential section of the same sample (Figure 1F). The expression
level of TGF-b1 mRNA does not have any associations with those
of TGF-b receptors (Table 1). TGF-b1 mRNA was also occasion-
ally expressed by inflammatory cells. TGF-b1 mRNA was occa-
sionally found in vascular endothelial and smooth muscle cells,
but was absent in neutrophils (data not shown).
Colorectal adenoma
Adenoma cells in 11/11 (100%) cases expressed TGF-b RI mRNA
as strongly as normal colorectal epithelial cells did (Figure 2B). In
addition, adenoma cells expressing TGF-b RII mRNA were often
closely associated with TGF-b RI-expressing cells (Figure 2C).
Strong signals for both TGF-b receptor mRNAs were found ubi-
quitously in colorectal adenoma cells, and there was no regional
localization within the crypts. TGF-b receptors were expressed
occasionally by inflammatory cells in the connective tissue. In
addition, a moderate signal of TGF-b1 mRNA was detectable in
adenoma cells (data not shown). Moderate immunoreactivities
with the TGF-b1 antibody were observed in the adenoma cells
(data not shown). Staining for TGF-b1 was associated with all
adenoma cells in cases with high expression levels of TGF-b1,
TGF-b RI and TGF-b RII mRNAs. In contrast to the faint expres-
sions for TGF-b receptor transcripts in some colorectal cancer
cells, the transcriptional and protein expression patterns of ligand
and its receptors in adenoma cells were basically identical to those
in normal colorectal cells. Moreover, these expression patterns did
not vary with tumour differentiation.
Northern blot hybridization analyses
To clarify the cell type-specific differences in expression of TGF-
b1 and TGF-b receptor mRNA between normal epithelial and
colorectal tumours quantitatively, levels of TGF-b1 and TGF-b
receptor mRNAs from normal epithelial were compared to those
for colorectal adenoma and cancer by Northern blot hybridization
200 M Matsushita et al
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analyses (Figure 3). We chose cancer cells from the patient in
Figure 1, and adenoma cells from the patient in Figure 2. GAPDH
expression was used as an internal control. The resulting differ-
ences in the expression of TGF-b1, TGF-b RI and RII mRNAs
shown in Figure 3A are graphically represented in Figure 3B.
A single 2.5 kb TGF-b1 mRNA species was detected in poly-A
mRNA isolated from normal epithelial, adenoma and cancer cells:
poly-A fractions isolated from cancer cells showed more expres-
sion in normal epithelial and adenoma cell fractions. TGF-b RI
mRNA (5.5 kb) and RII mRNA (5.5 kb) species were clearly
detectable in normal epithelial and adenoma cells, but exhibited
much lower expression levels in cancer cells (Figure 3A).
Quantitation of the TGF-b1, TGF-b RI and RII mRNAs by scan-
ning densitometry (Figure 3B) also revealed that the levels of
expression of TGF-b RI and RII mRNAs in cancer cells were 15%
and 36% of normal epithelial cells, respectively, in spite of a slight
increase of mRNA expression for TGF-b1. In support of the in situ
hybridization analyses shown in Figure 1, TGF-b receptor mRNA
species were scarcely expressed in the colorectal cancer cells.
TGF-b1 immunoreactivity
Strong and moderate immunoreactivities with the anti-TGF-b1 anti-
body were observed in the colorectal cancer cells of all cases.
(Table 1, Figure 4B and 4C). TGF-b1 in the cancer cells was stained
more intensely than that in normal epithelial cells. The antibody
absorbed with excess TGF-b1 peptide does not react with the
antigen on the tissue sections (Figure 4D). Immunohistochemical
staining for TGF-b1 protein was associated with all cancer cells in
cases with high expression levels of TGF-b1 mRNA and the expres-
sion of TGF-b RII mRNA even without expression of TGF-b RI
transcript (Table 1, Figure 1 and 4). In addition, lamina propria and
the collagen fibre in the connective tissue occasionally showed
fibrillar staining for TGF-b (Figure 4C).
Expressions of TGF-b receptor mRNAs and the
deposition of TGF-b1 protein in vimentin-positive
fibroblast-like cells and endothelial cells in the
colorectal cancer stroma
Next, we focused on cancer and stromal interactions, and studied
the expressions of TGF-b receptor transcripts as well as the loca-
tion of TGF-b1 protein in the colorectal cancer stroma.
Figure 5A illustrates the staining of the colorectal cancer tissue
for TGF-b1 protein and indicates that TGF-b1 protein was
deposited in the malignant carcinoma cells (arrowhead), the
tumour-associated vascular endothelial cells (open arrow) and in
the fibroblast-like cells (closed arrow) in the surrounding tissue
stroma. In addition, the results of in situ hybridization revealed a
A
B
Figure 6 Immunofluorescence study of Smad4 in colorectal adenoma and cancer cells after TGF-b stimulation. Colorectal adenoma and cancer cells were
incubated in the absence or presence of TGF-b for 1 h. Smad 4 was localized in the cells by immunofluorescence using specific antisera. Smad 4 staining was
predominant in the cytoplasm in the absence of TGF-b. After TGF-b stimulation, nuclear staining for Smad 4 was observed in adenoma cells (A), by contrast,
the staining remained predominant in the cytoplasm of cancer cells (B)
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moderate reaction with the riboprobe for TGF-b RI, which
suggests that vimentin-positive vascular endothelial cells (open
arrow) and irregular, spindle-shaped, fibroblast-like cells (closed
arrow) were synthesizing messages for TGF-b RI (Figure 5B, C).
Cells expressing TGF-b RII mRNA were often closely associated
with TGF-b RI-expressing fibroblast-like cells and endothelial
cells in colorectal cancer stroma (Figure 5D). The observation that
endothelial cells and fibroblast-like cells in the cancer stroma
synthesize TGF-b receptors, coupled with immunohistochemical
staining of TGF-b1 in these cells and the strong or moderate
expression of TGF-b1 transcripts in the colorectal cancer cells
(Table 1, Figure 1E and Figure 3), suggests that the endothelial
cells and the fibloblast-like cells have potential ability to bind
TGF-b secreted from the colorectal cancer cells.
Translocation of Smad 4 in colorectal adenoma cell and
cancer cells after stimulation with TGF-b1
Signalling by TGF-b receptors is mediated by the recently identi-
fied Smad protein family. The activated TGF-b receptor induces
phosphorylation of two such proteins, Smad 2 and Smad 3, which
form hetero-oligomeric complexes with Smad 4 that translocate to
the nucleus, where they then regulate transcriptional responses.
To study for TGF-b signal transduction in adenoma cells and
colorectal cancer cells directly, we first cultured adenoma cells,
which have both TGF-b receptors, and colorectal cancer cells from
patient no. 4, who expressed TGF-b RI faintly. Northern blot
analyses with Smad-specific probes revealed the Smad 2, 3 and 4
mRNA expressions, and no mutations of these Smads were
observed (data not shown). Then, we investigated whether treat-
ment of these cells with TGF-b leads to an accumulation of Smad
4 protein in the nucleus.
The subcellular localization of Smad 4 in colorectal adenoma
cells and cancer cells before or after stimulation with TGF-b was
analysed by immunofluorescence using specific antisera. As a
control, rabbit IgG did not react with the antigen on the cells (data
not shown). In the absence of ligand, staining for Smad 4 was seen
predominantly in the cytoplasm of the cells, whereas after stimula-
tion with TGF-b1 for 1 h, the staining in adenoma significantly
accumulated in the nucleus (Figure 6A). In contrast, the staining
remained unaltered in the cytoplasm of the cancer cells upon 
TGF-b1 stimulation (Figure 6B). These results indicated that the
colorectal cancer cells expressing only faintly TGF-b RI, cannot
transduce TGF-b signal, but the adenoma cells can.
DISCUSSION
TGF-b in normal colorectal epithelial cell
Our results demonstrated that both TGF-b RI and RII mRNAs
were strongly expressed in normal colorectal epithelial cell. In situ
hybridization and immunohistochemistry of the ligand also
suggested that TGF-b1 is produced by, and is present within, the
colorectal epithelium, which is consistent with previous reports
(Barnard et al, 1989; Koyama et al, 1989; Avery et al, 1993;
Barnard et al, 1993). TGF-b inhibits the growth of rat intestinal
(jejunal) epithelial cell line (Kurokawa et al, 1987; Barnard et al,
1989) and can directly induce apoptoic cell death (Cui et al, 1995).
Thus, TGF-b may play an important role in mediating differentia-
tion and cell death in an autocrine fashion.
TGF-b in colorectal adenoma
As in the normal crypts, there was codistribution of TGF-b RI and
TGF-b RII within epithelial cells, with similar staining intensity
for both of these receptors. Furthermore, Smad 4 translocated into
nucleus on treatment of the adenoma cells with TGF-b. Taken
together with the recent finding that TGF-b is a suppresser of
colorectal adenoma cells in vitro (Manning et al, 1991), our results
lead to the conclusion that the signal transduction pathway of
TGF-b is intact in colorectal adenoma cells.
Autocrine
Paracrine
Normal colorectal
epithelial cells Cancer cells Fibroblast
Endothelial cells
Figure 7 Differential sensitivity of TGF-b for normal colorectal epithelial/adenoma cells and cancer cells. In normal colorectal epithelial/adenoma cells, TGF-b
inhibits cell growth through TGF-b receptors by an autocrine mechanism. Without TGF-b receptors in cancer cells, its growth-inhibitory signal cannot be
propagated. TGF-b secreted from colorectal cancer cells is involved in angiogenesis and stroma formation by binding to TGF-b receptors on endothelial cells
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However, using APC knockout mouse, Oshima et al (1997) and
Zhang et al (1997) reported the distribution of TGF-b RII in normal
gut and its down-regulation in intestinal adenoma. In addition,
Akiyama et al (1997) found that eight of 13 replication error pheno-
type (RER)-positive adenomas had TGF-b RII mutations in the
polyadenine tract and these mutations were present in all adenomas
with moderate atypia. These reports suggest that TGF-b RII inacti-
vation is an early event contributing to the formation of premalig-
nant colon neoplasms. Although we sequenced TGF-b RII cDNA
from ten adenoma tissues, no mutants were found (data not shown).
TGF-b and malignant progression
Many transformed cell lines compared with their normal counter-
parts are resistant to the growth-inhibitory effects of TGF-b.
However, it remains to be elucidated which mechanism of TGF-b
resistance occurs in human tumour cells as well as at which step in
the multistep process of carcinogenesis cells become resistant to
TGF-b.
To understand the functional implications of these mechanisms
in vivo, we performed in situ hybridization and Northern blot
hybridization for TGF-b receptors. This work for the first time
extends studies on the transcriptional levels of TGF-b receptors in
human tissues to colorectal cancer, and shows that TGF-b receptor
mRNAs were only faintly expressed in eight of 22 colorectal
cancers, and that down-regulation was greater for TGF-b RI than
for TGF-b RII (Figure 1A, C and Figure 3). As for the meaning of
down-regulation of TGF-b RI, Wang et al (1996) reported that low
TGF-b RI expression levels in a human colon carcinoma cell can
be a limiting factor for TGF-b response and autocrine-negative
activity, which was supported by evidence that increased TGF-b
RI expression in the cell line with a low level of TGF-b RI expres-
sion increased TGF-b responsiveness as well as that autocrine-
negative activity reduced in vivo malignancy. These are the major
mechanisms for TGF-b resistance in human colorectal cancer.
Our findings demonstrate that reduced TGF-b receptor tran-
scripts develop relatively late in the evolution of colorectal cancer.
Furthermore, treatment of colorectal cancer cells with TGF-b does
not lead to an accumulation of Smad 4 protein in the nucleus,
although the translocation was seen in adenoma cells. These
results confirm and extend previous findings that the conversion of
the non-tumorigenic phenotype of human colonic adenoma cell
line to a tumorigenic phenotype is accompanied by a reduced
response to the growth inhibitory effects of TGF-b (Manning et al,
1991); moreover, intestinal polyps developed into more malignant
tumour than those in the single ApcD716 heterozygote by induction
of Smad 4 mutation into the ApcD716 knockout mouse (Takaku et
al, 1998). Therefore, abnormalities of the TGF-b signal transduc-
tion pathway, including receptors and Smad, play a significant role
in the malignant progression of colorectal cancer.
Immunohistochemical staining for TGF-b1 protein was associ-
ated with all cancer cells in cases with high expression levels of
TGF-b1 mRNA and the expression of TGF-b RII mRNA even
without expression of TGF-b RI transcript. This can be explained
by previous reports and our own findings that the homodimer of
TGF-b RII binds to its ligand in the absence of TGF-b RI,
however, TGF-b can only induce its multiple biological actions
through the heterodimic complex of TGF-b RI and TGF-b RII
(Attisano et al, 1994).
Although the mechanism of reduction of TGF-b RI transcripts
is currently unknown, several reports analysed the promoter
region of TGF-b RII to pursue the transcriptional mechanism of
this gene. Bae et al (1995) identified two positive regulatory
elements (PRE1 and PRE2) and at least one negative regulatory
element (NRE) in the promoter region of TGF-b RII. Furthermore,
Kim et al (1997) reported that an absolute reduction of TGF-b RII
mRNA followed by transformation of keratinocytes with E1A
oncogene is the result of decreased expression of unidentified tran-
scription factor complexes that interact with PRE1 and PRE2.
Therefore, we speculate that the down-regulation of TGF-b RII in
human colorectal cancer is caused by a decrease of these transcrip-
tion factors. Furthermore, our findings, as presented in the current
study, demonstrate that a transient down-regulation of TGF-b RII
occurs in hepatocytes; however, the levels of TGF-b RII expres-
sion remain high in non-parenchymal cells during liver regenera-
tion (Date et al, 1998). These results lead us to conclude that these
transcription factors are specific to epithelial cells.
Our results demonstrate that human colorectal cancer cells
express higher levels of TGF-b1 transcripts than their normal
counterparts. This raises the question of which biological func-
tions of TGF-b secreted from human colorectal cancer have a
positive effect on cancer development if the cancer cells lose the
ability to respond to the peptide. It has been postulated that TGF-b
stimulates tumour growth indirectly via paracrine effects on
stromal elements of the tumour. Our results support this hypothesis
because the expression of TGF-b receptors was observed in
mesenchymal cells such as fibroblasts and endothelial cells. TGF-
b induces the net accumulation of extracellular matrix protein not
only by elevating extracellular matrix protein expression but also
by strongly up-regulating the inhibitors of extracellular matrix
degrading enzymes and down-regulating extracellular matrix
degrading enzymes (Ignotz et al, 1986; Laiho et al, 1986; Edwards
et al, 1987). Directly, or through other cells that it attracts and
stimulates, TGF-b1 can also induce formation of new blood
vessels in vivo (Roberts et al, 1986). This response might seem
paradoxical given the strong growth inhibitory effect of TGF-b1
and TGF-b3 on endothelial cell monolayer cultures (Fráter-
Schröder et al, 1986; Heinmark et al, 1986). However, it should be
noted that, under certain culture conditions, TGF-b does not
inhibit endothelial cell growth, and endothelial cells tend to orga-
nize into tubular structures reminiscent of an angiogenic process
(Madri et al, 1988).
In summary, down-regulation of TGF-b receptors may play a
corresponding role in development of the resistance to the growth-
inhibitory effects of TGF-b, that is, aggressive cell growth,
demonstrated by human colorectal cancer. Moreover, the TGF-b1
production in colorectal cancer as well as the presence of TGF-b
receptors in endothelial cells and fibroblasts around colorectal
cancer cells strongly suggests that this multipotential cytokine is
involved in angiogenesis and stroma formation (Figure 7).
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